1. Home
  2. MIST vs SKYX Comparison

MIST vs SKYX Comparison

Compare MIST & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • SKYX
  • Stock Information
  • Founded
  • MIST 2003
  • SKYX 2004
  • Country
  • MIST Canada
  • SKYX United States
  • Employees
  • MIST N/A
  • SKYX N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • SKYX Building Products
  • Sector
  • MIST Health Care
  • SKYX Consumer Discretionary
  • Exchange
  • MIST Nasdaq
  • SKYX Nasdaq
  • Market Cap
  • MIST 89.8M
  • SKYX 99.2M
  • IPO Year
  • MIST N/A
  • SKYX 2022
  • Fundamental
  • Price
  • MIST $1.60
  • SKYX $1.01
  • Analyst Decision
  • MIST Strong Buy
  • SKYX Strong Buy
  • Analyst Count
  • MIST 2
  • SKYX 2
  • Target Price
  • MIST $7.50
  • SKYX $3.50
  • AVG Volume (30 Days)
  • MIST 1.8M
  • SKYX 970.8K
  • Earning Date
  • MIST 08-07-2025
  • SKYX 08-11-2025
  • Dividend Yield
  • MIST N/A
  • SKYX N/A
  • EPS Growth
  • MIST N/A
  • SKYX N/A
  • EPS
  • MIST N/A
  • SKYX N/A
  • Revenue
  • MIST N/A
  • SKYX $87,412,993.00
  • Revenue This Year
  • MIST N/A
  • SKYX $18.90
  • Revenue Next Year
  • MIST N/A
  • SKYX $29.10
  • P/E Ratio
  • MIST N/A
  • SKYX N/A
  • Revenue Growth
  • MIST N/A
  • SKYX 12.42
  • 52 Week Low
  • MIST $0.63
  • SKYX $0.77
  • 52 Week High
  • MIST $2.75
  • SKYX $2.14
  • Technical
  • Relative Strength Index (RSI)
  • MIST 83.15
  • SKYX 34.76
  • Support Level
  • MIST $1.86
  • SKYX $0.97
  • Resistance Level
  • MIST $1.97
  • SKYX $1.13
  • Average True Range (ATR)
  • MIST 0.14
  • SKYX 0.09
  • MACD
  • MIST 0.06
  • SKYX -0.01
  • Stochastic Oscillator
  • MIST 100.00
  • SKYX 12.39

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About SKYX SKYX Platforms Corp.

SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.

Share on Social Networks: